Carlos Andrés Carvajal Fierro

Mr. Carlos Andrés Carvajal Fierro

Instituto Nacional de Cancerología, Bogotá, Colombia
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
CFCarlos Andrés Carvajal Fierro
Carlos Andrés Carvajal Fierro
FGFelipe González
Felipe González
RBRafael Beltrán
Rafael Beltrán
RBRicardo Buitrago
Ricardo Buitrago
ARAmelia de Los Reyes
Amelia de Los Reyes
JCJosé Carreño
José Carreño

22 February 2021 in Revista Colombiana de Cancerología
Verified
Journal Article
Closed access
PDF file
MAMartha-Liliana Alarcón
Martha-Liliana Alarcón
RBRicardo Brugés
Ricardo Brugés
CFCarlos Andrés Carvajal Fierro
Carlos Andrés Carvajal Fierro
CVCamilo Vallejo
Camilo Vallejo
RBRafael Beltrán
Rafael Beltrán
Objetivos: El objetivo fue describir las características demográficas, histopatológicas, biología molecular tumoral y estadificación de los pacientes con cáncer de pulmón de célula no pequeña atendidos entre diciembre de 2013 y diciembre 2018 en el Instituto Nacional de Cancerología. Métodos: Estudio descriptivo de corte transversal Resultados: Se incluyeron 392 pacientes con cáncer de pulmón de célula no pequeña, la mediana de edad fue 65.9 años (rango, 28,9 a 88,9 años). 198(50,5%) pacientes fueron mujeres, obteniendo una relación hombre mujer 1:1. El 90.6% de los casos eran mayores de 50 años. Antecedente de tabaquismo se presentó en 211(53,8%) pacientes, 75.8% de la población masculina y 32,3% de la población femenina eran fumadores. El adenocarcinoma se encontró en 293(74,7%) pacientes y el carcinoma escamocelular en 73(18,6%) pacientes. La estadificación patológica fue: estadío I en 22(5,6%) pacientes, estadío II en 18(4,6%), estadío III en 40(10,2%) pacientes, estadío IV en 311(79,3%) pacientes y no hubo dato en 1 solo paciente. Se detectó la mutación del EGFR en 21,2% de los pacientes. Los reordenamientos de ALK se identificaron en 4,6% de los pacientes y el PDL 1 solo se midió en el 9% de la población. Conclusiones: este estudio nos muestra el panorama general del cáncer de pulmón de célula no pequeña en la población colombiana, en donde la mayoría de los pacientes se diagnostican en estadios avanzados de la enfermedad y nos expone la necesidad de nuevas estrategias para la detección temprana y el acceso oportuno de los pacientes con cáncer de pulmón.

1 January 2023 in Cancer Control
Verified
Journal Article
Open access
DBDiego-Felipe Ballén
Diego-Felipe Ballén
CFCarlos Andrés Carvajal Fierro
Carlos Andrés Carvajal Fierro
RBRafael Beltrán
Rafael Beltrán
MAMartha-Liliana Alarcón
Martha-Liliana Alarcón
CVCamilo Vallejo-Yepes
Camilo Vallejo-Yepes
RBRicardo Brugés-Maya
Ricardo Brugés-Maya
Objective: To describe the survival outcomes of metastatic non-small cell lung cancer patients with limited access to immunotherapy and targeted therapy in a cancer reference center in Colombia. Methods: A retrospective analysis of metastatic non-small cell lung cancer patients treated between 2013 and 2018 was performed, majority diagnosed with adenocarcinoma. It was carried out in a public cancer reference center that provides care to patients of low and middle socioeconomic status. Overall survival and progression-free survival were evaluated by Kaplan–Meier analysis and log-rank test. A Cox regression model was performed for univariate and multivariate analysis. Results: 209 patients were included with majority of adenocarcinoma (79.5%). First-line treatment was cytotoxic chemotherapy (50.2%), EGFR-targeted therapy (14.8%), chemoimmunotherapy (1.9%), and ALK-targeted therapy (1.4%). 31.6% received best supportive care. Median time of follow-up was 13 months, median overall survival was 11.2 months (95% CI, 7.9–14.4), 13 months for adenocarcinoma (95% CI, 8.1–17.9), and 2.5 months for squamous cell carcinoma (95% CI, 0.6–4.4) ( P < .001). Median progression-free survival was 9.3 months (95% CI, 7.9–10.7) without differences according to the type of first-line therapy. Median time-to-treatment was 55 days and only 54% of patients with a tested actionable mutation in EGFR received an EGFR-targeted therapy as the first-line treatment. Multivariate analysis showed that squamous cell carcinoma histology and receiving best supportive care were independent factors for worse overall survival ((HR:1.8, 95% CI, 1.076–3.082, P=.026) and (HR:14.6, 95% CI, 8.921–24.049, P < .001), respectively). Meanwhile, squamous cell carcinoma histology was an independent factor for worse progression-free survival (HR:3.4, 95% CI, 1.540-7.464, P=.002). Conclusions: Despite advances in precision medicine, during the study period, cytotoxic chemotherapy was the most used treatment in our patients. Furthermore, about a third of them received best supportive care. The use of targeted therapies has been restricted by access to molecular diagnosis and remained low until 2018. Access to immunotherapy should be prioritized.

13 May 2022 in Frontiers in Surgery
Verified
Journal Article
Open access
CFCarlos Andrés Carvajal Fierro
Carlos Andrés Carvajal Fierro
HFHelena Facundo
Helena Facundo
PPPaola Puerto
Paola Puerto
JCJosé Carreño
José Carreño
RBRafael Beltrán
Rafael Beltrán
Purpose: This study aimed to describe the survival outcomes and factors associated with prognosis in patients undergoing pulmonary metastasectomy with colorectal cancer (CRC) in a cancer center in South America.Material and methods: A retrospective analysis of patients that underwent lung metastasectomy due to CRC at National Cancer Institute (INC), Colombia between 2007 and 2017 was performed and Kaplan-Meier survival analysis along with log-rank test and Cox regression multivariate analysis were completed.Results: Seventy-five patients with colorectal adenocarcinoma were included in the study. Of them, 57.3% were women with a median age of 62 years [interquartile ranges (IQR): 18.5]. For 45.3% the adenocarcinoma was located in the rectum and 29.3% had stage IV at diagnosis. 56% had a history of controlled extrapulmonary metastasis and 20% of the cases had a history of the metastasis of the liver. The median follow-up was 36.8 months (IQR: 27.4). Three-year and five-year overall survival (OS) was 57.5% [95% confidence interval (CI), 47.0–70.4] and 33.2% (95% CI, 23.4–47.2), respectively. Patients with bilateral, more than one pulmonary metastasis, abnormal postmetastasectomy carcinoembryonic antigen (CEA), history of liver metastasis, and disease-free interval (DFI) ≤12 months had worse OS. Three-year and five-year disease-free survival (DFS) was 30.1% (95% CI, 20.8–43.6) and 21.6% (95% CI, 13.0–35.9), respectively. Bilateral, more than one pulmonary metastasis, and patients with stage IV at diagnosis had the worst DFS. Multivariate analysis in the Cox regression model showed that abnormal postmetastasectomy CEA [Hazard Ratio (HR):1.97, 95% CI, 1.01–3.86, p = 0.045] and DFI ≤ 12 months (HR: 3.08, 95% CI, 1.26–7.53, p = 0.014) were independent factors for worst OS.Conclusions: The OS found falls within the wide range described in the world literature but interestingly it falls at the bottom end of this range. The factors associated with worst survival were identified as bilateral, more than one pulmonary metastasis, abnormal postmetastasectomy CEA, history of liver metastasis, and DFI ≤12 months.Contribution to the field: Pulmonary metastasectomy is the standard of care in patients with metastatic CRC. However, the literature supporting this conduct is based on retrospective studies and the only randomized controlled trial conducted to date was stopped due to poor recruitment. Limited information is available in South America about survival and factors associated with prognosis in patients with metastatic CRC. While this study is another series that adds to the many studies across the world that describe the use of pulmonary metastasectomy in CRC, it presents critical data as it is one of the few studies carried out in South America. As described in a wide range of world literature, OS found falls in patients that underwent lung metastasectomy due to CRC however; interestingly, in the South American population analyzed here it falls at the bottom end of this range. This may be explained by a large number of patients included with a history of extrapulmonary metastasis as well as may reflect inadequate patient access to reference cancer centers in Colombia. Factors associated with worst survival in our population were bilateral, more than one pulmonary metastasis, abnormal postmetastasectomy CEA, history of liver metastasis, and interval from diagnosis to development of pulmonary metastasis ≤12 months.

27 June 2021 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
CFCarlos Andrés Carvajal Fierro
Carlos Andrés Carvajal Fierro
ARAna María Ramirez
Ana María Ramirez
SGSilvia Guerrero‐Macías
Silvia Guerrero‐Macías
RBRafael Beltrán
Rafael Beltrán
RBRicardo Buitrago
Ricardo Buitrago
JCJosé Carreño
José Carreño

29 June 2023 in Revista Colombiana de Cancerología
Verified
Journal Article
Open access
PDF file
FSFernando Alvarado Sarzosa
Fernando Alvarado Sarzosa
SJStella Isabel Martínez Jaramillo
Stella Isabel Martínez Jaramillo
LHLuis Gerardo García-Herreros Hellal
Luis Gerardo García-Herreros Hellal
RJRafael José Beltrán Jiménez
Rafael José Beltrán Jiménez
JRJuan David Zuluaga Restrepo
Juan David Zuluaga Restrepo
CFCarlos Andrés Carvajal Fierro
Carlos Andrés Carvajal Fierro
Introducción: En Colombia, la información de la supervivencia de los pacientes con cáncer de pulmón tratados en estadio temprano es limitada. El objetivo de este estudio fue analizar los desenlaces clínicos y los factores asociados al pronóstico de los pacientes con cáncer de pulmón de célula no pequeña (CPCNP) con manejo quirúrgico en tres instituciones de Bogotá. Métodos: Estudio observacional, analítico, retrospectivo, multicéntrico. Resultados: Se incluyeron 101 pacientes con una mediana de edad de 69 años (IQR 63-75), de ellos, 56 (55,4 %) mujeres. Ocho (7,9 %) pacientes tenían un estadio patológico 0; 83 (82,2 %), estadio I y 10 (9,9 %), estadio II. La supervivencia libre de enfermedad (SLE) a tres años de los pacientes con estadios 0, I y II fue de 100 %, 97 % y 58 %, respectivamente. La supervivencia global (SG) a tres años de todos los pacientes incluidos fue del 94 %. La SG con y sin recaída fue de 78 % y 96 %. Se encontraron asociaciones estadísticamente significativas entre recaída y estadio II (P< 0,001), recaída y T3 (P=0,048), recaída y N1 (P<0,001) y recaída y compromiso de la pleura visceral (P=0,002). La única asociación encontrada con el fallecimiento de los pacientes fue la recaída (P=0,002). Conclusiones: El estadio patológico y algunas características especiales del TNM, ser T3, la presencia de N1 y la invasión de la pleura visceral fueron factores determinantes en la SLE. Por otro lado, el único factor que se asoció con peor SG fue la recaída.